Novel milk-based oral formulations: Proof of concept

International Journal of Pharmaceutics

Volumn 390, Issue 2, 2010, Pages 150-159

  Charkoftaki, Georgia ^a   Kytariolos, John ^a   Macheras, Panos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Aspirin; Cyclosporine; Danazol; Milk; NSAIDs; Oral formulations

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; BUFFER; CYCLOSPORIN A; DANAZOL; GLYCINE; KETOPROFEN; MEFENAMIC ACID; MELOXICAM; MILK FAT; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATE; SALOSPIR; SODIUM HYDROXIDE; TENOXICAM; TOLFENAMIC ACID; UNCLASSIFIED DRUG; WATER;

ALKALINITY; AQUEOUS SOLUTION; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MIXTURE; DRUG SOLUBILITY; DRUG SOLUTION; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; IONIZATION; LIPOPHILICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MILK; NORMAL HUMAN; PH MEASUREMENT; PRIORITY JOURNAL; REPLICATION STUDY; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BUFFERS; CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; DANAZOL; ETHANOL; HUMANS; MALE; MILK; SOLUBILITY; THIAZINES; THIAZOLES;

EID: 77951499450     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.01.038     Document Type: Article

References (52)

1. Aunins J.G., Southard M.Z., Myers R.A., Himmelstein K.J., Stella V.J. Dissolution of carboxylic acids. III. The effect of polyionizable buffers. J. Pharm. Sci. 1985, 74:1305-1316.
2. Avdeef A., Burger C.M., Brownell C. pH-Metric solubility. 2. Correlation between the acid-base titration and the saturation shake-flask solubility-pH methods. Pharm. Res. 2000, 17:85-89.
3. Bae J.W., Kim M.J., Jang C.G., Lee S.Y. Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2007, 8:69-73.
4. Bakatselou V., Oppenheim R.C., Dressman J.B. Solubilization and wetting effects of bile salts on the dissolution of steroids. Pharm. Res. 1991, 8:1461-1469.
5. Dial E.J., Romero J.J., Lichtenberger L.M. Gastroprotection by dairy foods against stress-induced ulcerogenesis in rats. Dig Dis. Sci. 1995, 11:2295-2299.
6. Gad Kariem E.A., Abounassif M.A., Hagga M.E., Al-Khamees H.A. Photodegradation kinetic study and stability indicating assay of danazol using high-performance liquid chromatography. J. Pharm. Biomed. Anal. 2000, 23:413-420.
7. Galia E., Nicolaides E., Hörter D., Löbenberg R., Reppas C., Dressman J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 1998, 15:698-705.
8. Giraud M.N., Motta C., Romero J.J., Lichtenberger L.M. Interaction of indomethacin and naproxen with gastric surface-active phospholipids: a possible mechanism for the gastric toxicity of non-steroidal anti-inflammatory drugs (NSAIDs). Biochem. Pharmacol. 1998, 57:247-254.
9. Gourniezaki, K., 2008. Solubility studies of acetylsalicylic in milk. MSc Thesis. National and Kapodistrian University of Athens, Greece.
10. Gschwend M.H., Erenmemişoĝlu A., Martin W., Tamur U., Kanzik I., Hincal A.A. Pharmacokinetic and bioequivalence study of meloxicam tablets in healthy male subjects. Arzneimittelforschung 2007, 57:264-268.
11. Hu J., Johnston K.P., Williams R.O. Spray freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent versus organic/aqueous co-solvent systems. Eur. J. Pharm. Sci. 2003, 20:295-303.
12. Ismailos G., Reppas C., Dressman J.B., Macheras P. Unusual solubility behavior of cyclosporin A in aqueous media. J. Pharm. Pharmacol. 1991, 43:287-289.
13. Ismailos, G., 1999. In vitro and In vivo Studies on Cyclosporin Absorption Characteristics. PhD Thesis. National and Kapodistrian University of Athens, Greece.
14. Kees F., Bucher M., Schweda F., Gschaidmeier H., Burhenne J., Mikus G., Faerber L. Comparative bioavailability of the microemulsion formulation of cyclosporine (neoral) with a generic dispersion formulation (cicloral) in young healthy male volunteers. Ther. Drug Monit. 2006, 28:312-320.
15. Kumar S.G.V., Mishra D.N. Preparation and evaluation of solid dispersion of meloxicam with skimmed milk. Yakugaku Zasshi 2006, 126:93-97.
16. Lanza F.L. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal antiinflammatory drugs. Scand. J. Gastroenterol. 1989, 24:24-31.
17. Larrucea E., Arellano A., Santoyo S., Ygartua P. Study of the complexation behavior of tenoxicam with cyclodextrins in solution: improved solubility and percutaneous permeability. Drug Dev. Ind. Pharm. 2002, 28:245-252.
18. Larsen A., Holm R., Pedersen M.L., Müllertz A. Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis. Pharm. Res. 2008, 25:2769-2777.
19. Levis K.A., Lane M.E., Corrigan O.I. Effect of buffer media composition on the solubility and effective permeability coefficient of ibuprofen. Int. J. Pharm. 2003, 253:49-59.
20. Lichtenberger L.M. The hydrophobic barrier properties of gastrointestinal mucus. Annu. Rev. Physiol. 1995, 57:565-583.
21. Lichtenberger L.M., Wang Z.M., Romero J.J., Ulloa C., Perez J.C., Giraud M.N., Barreto J.C. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat. Med. 1995, 1:154-158.
22. Lichtenberger L.M., Ulloa C., Romero J.J., Vanous A.L., Illich P.A., Dial E.J. Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: combination therapy with antisecretory agents. Gastroenterology 1996, 111:990-995.
23. Ligumsky M., Grossman M.I., Kauffman G.L. Endogenous gastric mucosal prostaglandins: their role in mucosal integrity. Am. J. Physiol. 1982, 242:G337-G341.
24. Ligumsky M., Golanska E.M., Hansen D.G., Kauffman G.L. Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in the rat. Gastroenterology 1983, 84:756-761.
25. Macheras P., Koupparis M., Tsaprounis C. Drug dissolution in milk using the automated flow injenction serial dynamic dialysis technique. Int. J. Pharm. 1986, 33:125-136.
26. Macheras P., Reppas C. Studies on drug-milk freeze dried formulations. I: Bioavailability of sulfamethizole and dicumarol formulations. J. Pharm. Sci. 1986, 75:692-696.
27. Macheras P., Reppas C. Studies on drug-milk freeze dried formulations II: Effect of regenerated fluid volume on nitrofurnatoin bioavailability. J. Pharm. Sci. 1986, 75:1145-1150.
28. Macheras P., Koupparis M., Antimisiaris S. Effect of temperature and fat content on the solubility of hydrochlorothiazide and chlorothiazide in milk. J. Pharm. Sci. 1989, 78:933-936.
29. Macheras P., Koupparis M., Antimisiaris S. Drug binding and solubility in milk. Pharm. Res. 1990, 7:537-541.
30. Macheras P., Ismailos G., Reppas C. Bioavailability study of a freeze-dried sodium phenytoin-milk formulation. Biopharm. Drug Dispos. 1991, 12:687-695.
31. Marcelín-Jiménez G., Hernández J.A., Ángeles A.P., Contreras L., García A., Hinojosa M., Morales M., Rivera L., Martínez-Rossier L., Fernández A. Bioequivalence evaluation of two brands of meloxicam tablets (Promotion and Mobicox): Pharmacokinetics in a healthy female Mexican population. Biopharm. Drug Dispos. 2005, 26:167-171.
32. Mobic® (meloxicam) Tablets 7.5mg and 15mg. Prescribing information, Boehringer Ingelheim. Available at: (Accessed 02 November 2008). http://boehringer-ingelheim.com/.
33. Mutalik S., Anju P., Manoj K., Usha A.N. Enhancement of dissolution rate and bioavailability of aceclofenac: a chitosan-based solvent change approach. Int. J. Pharm. 2008, 28:279-290.
34. Rainsford K.D., Willis C. Relationship of mucosal damage induced in pigs by anti-inflammatory drugs to their effects on prostaglandin production. Dig. Dis. Sci. 1982, 27:624-635.
35. Ran Y., Zhao L., Xu Q., Yalkowsky S.H. Solubilization of cyclosporin A. AAPS Pharm. Sci. Technol. 2001, 2:E2.
36. Rasenack N., Müller B.W. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm. Res. 2002, 19:1894-1900.
37. Rasenack N., Hartenhauer H., Müller B.W. Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. Int. J. Pharm. 2003, 26:137-145.
38. Rasenack N., Steckel H., Müller B.W. Micronization of anti-inflammatory drugs for pulmonary delivery by a controlled crystallization process. J. Pharm. Sci. 2003, 92:35-44.
39. Robert A. Prostaglandins and the gastrointestinal tract. Physiology of the Gastrointestinal Tract 1981, 1404-1434. Raven Press, New York. L.R. Johnson (Ed.).
40. Rogers T.L., Johnston K.P., Williams R.O. Physical stability of micronized powders produced by spray-freezing into liquid (SFL) to enhance the dissolution of an insoluble drug. Pharm. Dev. Technol. 2003, 8:187-197.
41. Rogers T.L., Overhoff K.A., Shah P., Santiago P., Yacaman M.J., Johnston K.P., Williams R.O. Micronized powders of a poorly water soluble drug produced by a spray-freezing into liquid-emulsion process. Eur. J. Pharm. Biopharm. 2003, 55:161-712.
42. Sahin N.O., Arslan H. Inclusion complex of prednisolone with skimmed milk. Part I. Physicochemical characterization. Yakugaku Zasshi 2007, 127:1255-1261.
43. Seedher N., Bhatia S. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS Pharm. Sci. Technol. 2003, 4:E33.
44. Sheng J.J., Kasim N.A., Chandrasekharan R., Amidon G.L. Solubilization and dissolution of insoluble weak acid, ketoprofen: effects of pH combined with surfactant. Eur. J. Pharm. Sci. 2006, 29:306-314.
45. Stephenson B.C., Rangel-Yagui C.O., Pessoa Junior A., Tavares L.C., Beers K., Blankschtein D. Experimental and theoretical investigation of the micellar-assisted solubilization of ibuprofen in aqueous media. Langmuir 2006, 14:1514-1525.
46. Topaloglou Y., Yener G., Breitkreuz J. Preparation of sulindac with skimmed milk via freeze drying. Pharmazie 1998, 53:327-329.
47. Topaloglou Y., Yener G., Gonullu U. Inclusion of ketoprofen with skimmed milk by freeze-drying. Il Farmaco 1999, 54:648-652.
48. US Pharmacopeia 30-NF 25, 2007. US Pharmacopeial Convention. Rockville, MD.
49. Walstra P., Jenness R. Dairy Chemistry and Physics 1984, John Wiley & Sons, New York.
50. Whittle B., Hansen D., Salmon J.A. Gastric ulcer formation and cyclooxygenase inhibition in cat antrum follows parenteral administration of aspirin but not salicylate. Eur. J. Pharmacol. 1985, 116:153-157.
51. Wu K., Li J., Wang W., Winstead D.A. Formation and characterization of solid dispersions of piroxicam and polyvinylpyrrolidone using spray drying and precipitation with compressed antisolvent. J. Pharm Sci. 2009, 98:2231-2422.
52. Yeh M.K., Chang L.C., Chiou A.H. Improving tenoxicam solubility and bioavailability by cosolvent system. AAPS Pharm. Sci. Technol. 2009, 10:166-171.